A liquid biopsy is a principally non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring syndromes such as cancer. Liquid biopsy is the direct clinical application of two advances in the medical science, explicitly, human genome sequencing and increasing sensitivity of detecting approaches and assays. Liquid biopsy capitalizes on the qualitative and quantitative variance between dissimilar biomarkers such as cell-free DNA, circulating tumor cells (CTCs), cell-free RNA (cfRNA) fragments, methylated ctDNA, and miRNA in a patient's blood. Although some of such fragments are released even throughout other situations such as trauma, there prevails a quantitative difference in the method of their composition and concentration as well as their degree of disintegration.
According to the report analysis, ‘Liquid Biopsy Market: Current Analysis and Forecast
(2021-2027)’ states that the growth of the liquid biopsy
market is principally driven by growing prevalence of cancer, increasing implementation
of non-invasive diagnostic and monitoring approaches and growing preference of
personalized medicines. In addition, technological improvements, increasing government
initiatives to improve healthcare infrastructure and large availability
funding's for research and development for liquid biopsy is probable to underwrite
to the growth of liquid biopsy market throughout the forecast duration.
Based on product and service, the liquid biopsy market is sectored
into assay kits, instruments, and services. Among these, the assay kits segment
is projected to be the fastest-increasing segment in the product and services
market throughout the forecast period. Aspects such as the growing demand for
liquid biopsy tests, augmenting the applications of liquid biopsies, and the requirement
for reliable and precise assays are projected.
Region wise, North America constitutes a foremost market for
disposable medical device sensor and created revenue of USD XX million during
2020 due to the existence of well-established players in the region, emerging
investment in healthcare R&D by players etc., However, the Asia Pacific
region would augment at the greatest CAGR during the review period.
Additionally, companion diagnostics comprise tests or assays
intended to help healthcare providers in making treatment decisions for
patients rely on the best response to therapy. The co-development of companion
diagnostics with therapeutic products can progressively alter the drug
development procedure and commercialize drug candidates by yielding harmless
drugs with improved therapeutic efficacy speedily and cost-effectively. With
the augmented demand for high-priced specialist therapies and harmless drugs,
the market for companion diagnostics has great growth potential. The increasing
importance of companion diagnostics is also delivering the growth opportunities
for the liquid biopsy market. Therefore, in the near years, it is predicted
that the market of liquid biopsy will increase around the globe more actively
over the near future.
For More Information, refer to
below link:-
Follow Us:-
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249
